For research and educational purposes only. Not intended for human consumption.
Survodutide
Well Researched- •Phase 2/3 trials - 18.7% weight loss
- •MASH fibrosis improvement demonstrated
- •Dual GLP-1/GCGR mechanism detailed
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & MASH
Overview
What is Survodutide?
Survodutide (BI 456906) is an investigational dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist designed for once-weekly subcutaneous administration. This 29-amino acid peptide represents a novel approach to metabolic disease by simultaneously targeting energy intake reduction (via GLP-1R) and energy expenditure increase (via GCGR), showing robust efficacy in Phase 2/3 trials for obesity and MASH.
Key Benefits
Dual mechanism for superior weight loss, once-weekly dosing, demonstrated efficacy in obesity/MASH/T2D, ~6-day half-life enables convenient weekly dosing.
Mechanism of Action
Balanced agonism of glucagon receptors (increases energy expenditure, hepatic fat oxidation) and GLP-1 receptors (reduces appetite, slows gastric emptying) with ~6.5-day half-life enabling weekly dosing.
Molecular Information
Pharmacokinetics
Research Indications
Obesity Without Diabetes
Phase 2 trial showed 14.9% mean weight loss at 46 weeks with 4.8mg dose, 55% achieving ≥15% weight loss.
Obesity With T2D
Superior weight loss vs glp1-s (-8.7% vs -5.3%) at 16 weeks in head-to-head trial.
Sustained Weight Management
Dual mechanism addresses both energy intake and expenditure.
Research Protocols
Disclaimer: Survodutide is in Phase 3 trials and not yet approved. These protocols are based on clinical trial data. Consult a healthcare provider.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Obesity - Conservative Start | 0.6mg titrated over 24 weeks | Once weekly | Subcutaneous |
| Obesity - Standard Protocol | 3.6-6.0mg | Once weekly | Subcutaneous |
| MASH Treatment | 2.4-4.8mg | Once weekly | Subcutaneous |
| Type 2 Diabetes | 0.3-2.7mg | Once weekly | Subcutaneous |
Timing: Administer once weekly on the same day. Can be taken any time of day regardless of meals.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove vial from refrigerator and allow to reach room temperature (15-30 minutes)
Clean rubber stopper with alcohol swab
Draw prescribed amount of bacteriostatic water into syringe
Inject slowly down the side of vial to minimize foaming
Gently swirl vial - do not shake vigorously
Solution should be clear to slightly opalescent
Store reconstituted solution in refrigerator immediately
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Clear to slightly opalescent solution
Properly reconstituted should be clear without visible particles.
Sealed vial with intact stopper
Ensures sterility and proper storage.
Slight foam after reconstitution
Normal if disappears within minutes.
Cloudy solution or visible particles
Do not use - may indicate degradation.
Discoloration
Should be colorless when reconstituted.
What to Expect
- •Week 1-4: Possible nausea, reduced appetite during dose escalation
- •Week 4-8: Initial weight loss begins, improved satiety
- •Week 8-16: Progressive weight loss, improved energy levels
- •Week 16-24: Approaching steady-state levels
- •Week 24+: Sustained weight loss (average 15-19% at higher doses)
Side Effects & Safety
Side Effects
- •Common GI side effects: nausea (40-66%), diarrhea (25-49%), vomiting (15-41%)
- •Most GI effects occur during dose escalation
- •Heart rate may increase slightly (mean 2-5 bpm)
- •Not recommended in pregnancy or breastfeeding
- •Monitor blood glucose if on diabetes medications
When to Stop
- •Severe GI symptoms
- •Signs of pancreatitis
- •Significant heart rate changes
- •Allergic reactions
- •As directed by healthcare provider
References
3 StudiesPhase 2 Obesity Trial (2024)
Human | 0.6-4.8mg weekly | 46 weeks | 14.9% weight loss, 55% achieved ≥15%
In 387 participants with BMI ≥27, survodutide 4.8mg achieved 14.9% mean weight loss.
Phase 2 MASH Trial (2024)
Human | 2.4-6.0mg weekly | 48 weeks | 47-62% MASH improvement
In 293 participants with MASH and fibrosis, survodutide improved MASH in 47-62% vs 14% placebo.
Phase 2 T2D Trial (2023)
Human | 0.3-2.7mg weekly | 16 weeks | Superior to glp1-s
Survodutide achieved greater weight loss than glp1-s (-8.7% vs -5.3%) at 16 weeks.
Quick Start Guide
Research Disclaimer
Survodutide is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Survodutide must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Survodutide for any purpose. Consult qualified professionals for any research applications.